Selective adenosine receptor agents
CA 2013380 C · Owner: Aventis Pharma Inc. · Inventors: Lentz, Nelsen L.; Sunder, Shyam; Peet, Norton P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Adenosine analogues which act selectively at adenosine receptors and which act in general as adenosine antagonists are disclosed. From in vitro studies it is known that specific physiological effects can be distinguished as a result of this selectivity and that adenosine receptor activity in vitro correlates with adenosine receptor activity in vivo. Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which will enhance certain physiological effects while minimizing others such as, decreasing blood pressure without decreasing heart rate.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 29, 1990 and granted May 22, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 29, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 29, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.